Publication Date:
1985-02-01
Description:
〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Culliton, B J -- New York, N.Y. -- Science. 1985 Feb 1;227(4686):493-6.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/3880924" target="_blank"〉PubMed〈/a〉
Keywords:
Advisory Committees
;
Animal Experimentation
;
Clinical Trials as Topic
;
DNA, Recombinant
;
*Ethical Review
;
Ethics, Medical
;
Federal Government
;
Genetic Diseases, Inborn/*therapy
;
*Genetic Engineering
;
*Government Regulation
;
Humans
;
Informed Consent
;
Lesch-Nyhan Syndrome/therapy
;
National Institutes of Health (U.S.)
;
Risk Assessment
;
United States
;
which the technology of gene therapy and its potential application in humans have
;
been subjected. She summarizes the federal government's interest in this area,
;
ranging from the Office of Technology Assessment's report, Human Gene Therapy, to
;
the creation of the Working Group on Human Gene Therapy. The latter, a
;
subcommittee of the National Institutes of Health's Recombinant DNA Advisory
;
Committee, released a list of "points to consider" by researchers planning to
;
design and submit protocols to NIH for gene therapy research in humans. Culliton
;
notes that some of the questions that the working group asks potential
;
researchers "go beyond the usual" to address controversial areas of gene therapy
;
such as primate studies, public health considerations, public relations, patents,
;
and eugenics.
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
